MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea

K. Dashtipour, S. Isaacson, M. Lew, D. Chary, T. Clinch, R. Pahwa (Boca Raton, FL, USA)

Meeting: 2019 International Congress

Abstract Number: 84

Keywords: Botulinum toxin: Clinical applications: other, Sialorrhea

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To assess the safety, tolerability and effectiveness of repeated rimabotulinumtoxinB injections in adults with troublesome sialorrhea over a period of 1 year.

Background: Sialorrhea (drooling) is a common and troublesome feature of several neurological disorders, causing social embarrassment, perioral irritation, soiled clothing, swallowing impairment, and poor oral hygiene. Botulinum toxin type-B injections into the parotid and submandibular salivary glands reduce saliva production.

Method: This was a Phase 3, multicenter, open-label, outpatient study (NCT02610868). Subjects received rimabotulinumtoxinB (3500 U) on Day 1. Treatment was repeated when the subject returned to clinical baseline status (investigator judgment), with a treatment interval of 11-15 weeks. Dose reductions to 2500 U were permitted from cycle 2 for intolerability; subjects underwent scheduled dental exams.

Results: 187 subjects were enrolled. Etiologies treated included Parkinson’s disease (65.8%) and amylotrophic lateral sclerosis (13.9%). During the first treatment cycle, rimabotulinumtoxinBsignificantly reduced mean unstimulated salivary flow rate between baseline and Week 4 (reduction of -0.34±0.37 g/min, p <0.0001) and efficacy was maintained through Week 13 (p<0.0001).Clinical Global Impression of Change showed significant improvement from baseline to Week 4 post‑injection of every treatment cycle. Efficacy benefits were similar for treatment cycles 2-4. Most AEs were mild and well tolerated, only 5 subjects (2.7%) early discontinued due to an AE and <10% of subjects required a dose reduction for tolerability. Dry mouth was reported by the highest proportion of subjects in Session 1 (15.5%), followed by dental caries (7%). In Sessions 2 through 4, dental caries were reported by the highest proportion of subjects (8%-12%), followed by dry mouth (2-6%).

Conclusion: Long-term, repeat treatment with rimabotulinumtoxinBwas generally well-tolerated. The efficacy of repeat treatment was maintained for up to 1 year.

To cite this abstract in AMA style:

K. Dashtipour, S. Isaacson, M. Lew, D. Chary, T. Clinch, R. Pahwa. Long-term safety and efficacy of rimabotulinumtoxinB in the treatment of adult sialorrhea [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/long-term-safety-and-efficacy-of-rimabotulinumtoxinb-in-the-treatment-of-adult-sialorrhea/. Accessed June 12, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/long-term-safety-and-efficacy-of-rimabotulinumtoxinb-in-the-treatment-of-adult-sialorrhea/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley